Mirae’s core product is a conversational AI that turns everyday patient inputs—symptoms, behaviors, medications—into a structured, longitudinal view of disease for clinicians and patients. The platform combines patient-reported data with clinical context and peer-reviewed evidence to help detect flares earlier, summarize trends for care moments, and support clinician decision-making. The company is initially focused on inflammatory bowel disease and is deploying its platform with a leading U.S. health system to support model development and validation. Mirae builds on research from the University of Oxford’s Computational Health Informatics Lab and was co-founded by Dr. David Clifton and CEO Anuj Patel. The company announced $5.4 million in funding led by Oxford Science Enterprises to expand access and further develop its models and integrations.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026